EP1075464A1 - Novel process - Google Patents

Novel process

Info

Publication number
EP1075464A1
EP1075464A1 EP99908058A EP99908058A EP1075464A1 EP 1075464 A1 EP1075464 A1 EP 1075464A1 EP 99908058 A EP99908058 A EP 99908058A EP 99908058 A EP99908058 A EP 99908058A EP 1075464 A1 EP1075464 A1 EP 1075464A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
reaction mixture
flask
ether
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99908058A
Other languages
German (de)
English (en)
French (fr)
Inventor
Milind Rangaishenvi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801369A external-priority patent/SE9801369D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1075464A1 publication Critical patent/EP1075464A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Definitions

  • the present invention relates to novel process for the preparation of prostaglandin compounds which are useful as medicaments.
  • Prostaglandins are a family of 20-carbon fatty acids found in virtually all mammalian cells and are biosynthesised from C-20 polyunsaturated fatty acids via cyclooxygenase enzyme system (S. Bergstroem., Science, 157, 382, 1967).
  • PGs have been the focus of extensive efforts in synthetic chemistry.
  • increasing attention is being focused on PG analogs.
  • the nonavailability of suitable natural source coupled with their potential drug utility has led to the clinical development of a number of synthetic PG analogs.
  • both pharmacologically and clinically are analogs incorporating methyl groups into the prostaglandin skeleton at C-1.5 (a).
  • Carboprost is clinically listed for treatment of post partum haemorrage as an alternative to methylergometrine or where the latter has produced inadequate response.
  • Intramuscular injection of 250 mg of carboprost in sterile aqueous solution is the best therapy now available, very successful in cases ready for uterectomy due to bleeding not stopped by methergin etc. This has been registered for this indication in Sweden and India (available under the brand names Prostinefem in Sweden and Prosodin in India).
  • the most recent approach which is frequently used for the syntheses of PGs involves the conjugate addition of an organometallics to an ⁇ -substituted 4-hydroxy 2-cyclopentenone (M.P.L. Caton in "New Synthetic Routes to Prostaglandins"., Academic Press N.Y., pg 105, 1982 and F. Sato et al. dislike J. Org Chem., 59, 6153, 1994).
  • the two-component process consists of two independent but complementary routes: introduction of a o-side chain to an endo-enone bearing an ⁇ -side chain and introduction of ⁇ -chain to an ex ⁇ -enone bearing an o-side chain.
  • the present invention involves the use of enantiomerically pure e/ut ⁇ -enone (II) bearing an ⁇ -sidechain and the desired o-chain was introduced via conjugate addition of a higher order cuprate generated using an enantriomerically pure ⁇ -chain iodide (VI).
  • the delineated process describes the synthesis of en_io-enone (II) in an excellent optical purity (> 99% ee), following the alkylation chemistry of the stabilised carbanion and its resolution using the technique of ultrasound mediated enzymatic irreversible transesterification.
  • the invention therefore provides a process for the preparation of a compound of formula (I): HO * (I)
  • R 1 and R 2 are both hydrogen or together form a bond such that the groups OR 1 and R 2 form a carbonyl group.
  • R 1 and R 2 are both hydrogen.
  • the groups P and P which can be the same or different, can be any suitable oxygen protecting groups, for example tetrahydropyran and, in particular, silyl protecting groups such as t-butyldiphenylsilyl, dimethylphenylsilyl, triethylsilyl, t-butyldimethylsilyl (TBDMS), trimethylsilyl (TMS) and triisopropylsilyl .
  • P is TBDMS and P 1 is TMS.
  • the reaction of compounds of formula (II) and (HI) is carried out in a suitable solvent such as THF-hexane, THF-ether, preferably THF/ether.
  • a suitable solvent such as THF-hexane, THF-ether, preferably THF/ether.
  • the reaction is carried out at reduced temperature, for example at about -78°C.
  • the reaction is carried out in the presence of a Lewis acid, particularly in the presence of BF 3 .OE. 2 . It has been found that the use of BF 3 .OEt 2 not only activates the enone at low temperatures and drives the reaction to completion, but also circumvents the problem of dehydration at the C- 15 position.
  • the higher order cuprate of formula (El) is preferably generated using anorgano- lithium reagent, preferably butyl lithium.
  • Reduction of a compound of formula (IA) can be carried out using known reducing agents.
  • reduction of the cyclopentanone is preferably carried out using a selective reducing agent such as K-selectride to give the desired cyclopentanol isomer.
  • Reduction of the triple bond can be carried out using conventional techniques such as Lindlar hydrogenation.
  • protecting groups P and P 1 are both silyl groups deprotection of both groups can be achieved using a fluoride reagent such as TBAF in a suitable solvent such as THF.
  • a fluoride reagent such as TBAF
  • THF a suitable solvent
  • the cyclopentanone moiety is reduced, followed by deprotection of the groups P and P 1 followed by reduction of the triple bond to furnish the desired compounds of formula (I).
  • Hal is halogen in the presence of an organolithium reagent.
  • L is a group such as a -SePh to stabilise the carbanion generated and Hal is bromo or iodo, preferably iodo.
  • Compounds of formula (IV) in which L is SePh can be prepared from the corresponding enone and phenylselenyl chloride using literature procedures.
  • the enone can be prepared by protecting the corresponding alcohol, for example by treating with TBDMS chloride conventional conditions.
  • the compound of formula (III) is a suitable cuprate, in particular a higher order cuprate and preferably a hienyl cuprate, in particular dilithium [3-methyl, 3-(trimethylsilyl)oxy octyl ⁇ - 2-thienyl cyanocuprate of formula (D3A):.
  • Novel intermediates form a further aspect of the invention.
  • the title compound was prepared from the above ⁇ -alcohol according to the method of Carl Johnson et al., JACS, 110, 4726-35 (1988) as an oil, bp 110 - 113°C at 0.9 mm Hg.
  • the title compound was prepared according to the method of M. Minai, Jap. Patent., Kokai No. 62236, 1982.
  • a 3-necked 31itre r.b. flask was cooled under a stream of nitrogen gas and was fitted with mechanical stirrer through the centre neck.
  • Side arm was connected to a socket with gas inlet and a cold, finger condenser.
  • Another side arm was connected to a nitrogen inlet under static pressure.
  • the cold finger condenser was charged with dry ice-acetone mixture (-78°C) and the reaction flask was kept in an insulated bath.
  • Anhydrous ammonia gas (dried through a wash bottle containing KOH pellets) was bubbled at a steady rate through the gas inlet in an atmosphere of nitrogen, whereupon ammonia condenses into the reaction flask. It took around 2 hr.
  • the mother liquor from filitration was concentrated in vacuo using a rotary evaporator and kept in the refrigerator to get an additional lot of hemiphthalate ester (2 crop, 0.43 Kg, m p 61- 62°C).
  • the compound obtained (0.151 Kg) showed higher m p and hence was kept aside and taken up for the recovery of racemic octynol. Yield of hemiphthalate ester: 1.348 Kg, 71%.
  • the product was purified by silica gel chromatography eluting with ethyl acetate/petroleum ether. Yield of the pure product: 11.11 gm, 31.76 mmols, 70%.
  • step b To the above solution of the lower order cuprate was added the solution of vinyl lithium (step b) dropwise by means of a cannula over a period of 10 min at -22°C, washed with THF (5 ml) and the solution stirred at -22°C for a further 1 hr. to provide a homogenous higher order cuprate (clear solution, pale yellowish orange colour). The resulting cuprate solution was cooled to -78°C (dry ice-acetone bath).
  • This product was further purified by preparative reversed phase HPLC using a preparative ODS (C-18) SHIMPAK column (20 x 250 mm) and using a mobile phase of acetonitrite- water (1:1): UV detection: 210 nm.
  • the preparative HPLC was done in batches of 0.170 gm and the recovery of the pure carbonprost methyl ester of USP specifications was ⁇ 65%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP99908058A 1998-03-06 1999-03-04 Novel process Withdrawn EP1075464A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
INMA046598 1998-03-06
IN465MA1998 1998-03-06
SE9801369 1998-04-20
SE9801369A SE9801369D0 (sv) 1998-04-20 1998-04-20 Novel process
PCT/SE1999/000318 WO1999044990A1 (en) 1998-03-06 1999-03-04 Novel process

Publications (1)

Publication Number Publication Date
EP1075464A1 true EP1075464A1 (en) 2001-02-14

Family

ID=26324795

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99908058A Withdrawn EP1075464A1 (en) 1998-03-06 1999-03-04 Novel process

Country Status (9)

Country Link
EP (1) EP1075464A1 (pt)
JP (1) JP2002505321A (pt)
KR (1) KR20010041632A (pt)
CN (1) CN1292780A (pt)
AU (1) AU2757299A (pt)
BR (1) BR9908511A (pt)
CA (1) CA2327332A1 (pt)
HU (1) HUP0102710A2 (pt)
WO (1) WO1999044990A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
CN102336693B (zh) * 2010-07-21 2014-01-22 上海天伟生物制药有限公司 卡前列素氨丁三醇的晶体及其制备方法和用途
CN102816099A (zh) * 2011-06-09 2012-12-12 上海天伟生物制药有限公司 一种高纯度的卡前列素氨丁三醇及其制备方法和用途
CN104860860B (zh) * 2015-04-29 2017-09-19 东北制药集团股份有限公司 一种卡前列酯的纯化制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3728382A (en) * 1970-05-04 1973-04-17 Upjohn Co 15-methyl and 15-ethyl prostaglandin analogs
US3822303A (en) * 1971-10-19 1974-07-02 E Yankee Trimethyl silyl esters of prostaglandin e acids and esters and process therefor
GB1384024A (en) * 1972-04-14 1974-02-12 Searle & Co Process for the preparation of 3-hydroxy-2-3-hydroxy-1-octenyl- 5-oxocyclopentane-heptanoic acid and derivatives thereof
US4029691A (en) * 1974-05-01 1977-06-14 The Upjohn Company Prostaglandin A1 , analogs
EP0178139B1 (en) * 1984-10-08 1989-07-05 Teijin Limited Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof
US5447865A (en) * 1992-06-10 1995-09-05 Amprost Pharmaceutical, Inc. Method of resolution of hydroxy substituted cyclopentanone enantiomers using lipase and lithium salt complexation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9944990A1 *

Also Published As

Publication number Publication date
HUP0102710A2 (hu) 2001-12-28
KR20010041632A (ko) 2001-05-25
AU2757299A (en) 1999-09-20
WO1999044990A1 (en) 1999-09-10
JP2002505321A (ja) 2002-02-19
CN1292780A (zh) 2001-04-25
CA2327332A1 (en) 1999-09-10
BR9908511A (pt) 2000-11-21

Similar Documents

Publication Publication Date Title
Wilson et al. Stereoselective phosphine-catalyzed synthesis of highly functionalized diquinanes.
GB2099814A (en) 15-deoxy-16-hydroxy prostaglandins
EP1075464A1 (en) Novel process
JP6643308B2 (ja) プロスタグランジン及びプロスタグランジン類似体をもたらす２−置換−４−オキシ−シクロペント−２−エン−１−オンへのビニルホウ素化合物の金属触媒による非対称１，４−共役付加
EP0178139B1 (en) Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof
JPH10504321A (ja) フリル銅試薬を用いるプロスタグランジンｅ１、ｅ２およびこれらの類似体の調製法
JP2018529781A (ja) レゾルビンｅ１の全合成のための方法
CZ20003234A3 (cs) Nový způsob
EP0943607B1 (en) Process for the preparation of prostaglandins
Arnold Phosphoramidites as ligands for copper in catalytic asymmetric CC bond formation reactions with organozinc reagents
JP2839841B2 (ja) プロスタグランジンｅ１ 類の製造法、及びその合成中間体
JP2713333B2 (ja) イソカルバサイクリン類及びその製造法
KR920004190B1 (ko) 7-티아프로스타글란딘 e₁의 제조방법
JP2637339B2 (ja) ２，３―ジ置換―４―置換シクロペンタノン類の製造方法
US5206416A (en) Isocarbacyclin derivative
JPH062695B2 (ja) イソカルバサイクリン類の製造法
JPS62195358A (ja) （５ｅ）−プロスタグランジンｅ↓２類の製造法
JPS5838433B2 (ja) フエニル置換ｐｇｆ↓２−型化合物類の製造方法
JPS61189246A (ja) ２，３−二置換−４−置換シクロペンタノン類の製造法
White Asymmetric Synthesis of Prostaglandins
JPH064557B2 (ja) ２，３−二置換−４−置換シクロペンタノン類の製造法
JPH0680024B2 (ja) イソカルバサイクリン類の製造法
JPS6061564A (ja) ６−ニトロプロスタグランジンｆ類、その製造法及びその用途
JPS6156163A (ja) （５ｅ）―プロスタグランジンｅ↓２類
JPS647063B2 (pt)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 20001006;LV PAYMENT 20001006;MK PAYMENT 20001006;RO PAYMENT 20001006;SI PAYMENT 20001006

17Q First examination report despatched

Effective date: 20011214

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020425